Drug Trial Radar · NCT03740958
Argatroban Plus R-tPA for Acute Ischemic Stroke
Last checked: Nov 20, 2026Latest source record: Feb 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
808
Actual
Start
Dec 21, 2018
Primary completion
Jan 30, 2022
Study completion Jan 30, 2022
Sponsor
- Lead sponsor
- General Hospital of Shenyang Military RegionAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 14, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Acute ischemic stroke (AIS) is the most common type of stroke, which has high rate of morbidity, mortality and disability. A large number of studies have confirmed that the thrombolytic therapy can effectively open blood vessels and improve the functional prognosis of acute ischemic stroke. Therefore, all guidelines recommend intravenous thrombolysis as the first treatment of ischemic stroke patients within 4.5 hours of onset. However, about 1/3 patients receiving thrombolysis will have good prognosis, while a large number of patients will still be disabled and even dead. How to improve the neurological prognosis of thrombolytic patients has been a hot topic in the world. Recent studies have found that the combined application of argatroban and rt-PA in the treatment of AIS might improve the clinical prognosis and not significantly increase bleeding. Some studies have reported that the combined application of argatroban and rt-PA could improve the blood vessel opening rate, and prevent re-occlusion after opening. Based on the discussion, the present study is designed to explore the efficacy and safety of argatroban plus rt-PA in the treatment of AIS.
Conditions
- Stroke
Interventions
rt-PADrug
Intravenous throbolysis with 0.9mg/kg rtPA
ArgatrobanDrug
100 ug/kg bolus over 3 to 5 minutes was administered intravenously, followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of mRS (0-1)Time frame: 90±7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
General Hospital of ShenYang Military Region
Shenyang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.